{"product_id":"cagrilintide","title":"Cagrilintide","description":"\u003cdiv class=\"strapi-description text-sm text-[#4B5563] md:text-base line-clamp-6\"\u003e\n\u003cp\u003eCagrilintide research compound. Supplied as a lyophilized peptide for laboratory research applications.\u003c\/p\u003e\n\u003cp\u003ePurity-tested per lot.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only. Not for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"container px-3\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolecular Formula\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/#query=C194H312N54O59S2\"\u003eC194H312N54O59S2\u003c\/a\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eCAS\t\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e1415456-99-3\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolar Mass\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e4409 g\/mol\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eAmino Acid Sequence\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSynonyms\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eAM833, NN9838, long-acting amylin analog (LAAA), amylin receptor agonist, modified human amylin analog, acylated amylin analog, investigational amylin mimetic\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSolubility\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eSoluble in Water\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eOrganoleptic Profile\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWhite powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eComposition\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLyophilized powder - requires reconstitution\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How does Cagrilintide work?\" id=\"how-does-cagrilintide-work\"\u003eHow does Cagrilintide work?\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eAmong the studied Cagrilintide peptide benefits, Cagrilintide's mechanism of action may primarily involve its role as a long-acting amylin analog that may interact with the calcitonin receptor. The peptide may demonstrate enhanced receptor activity compared to native amylin, with potentially improved pharmacokinetic properties. Research suggests that Cagrilintide may work through multiple pathways:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eThe primary mechanism may involve the activation of amylin receptors in key brain regions, particularly the area postrema and other circumventricular organs. This activation may lead to enhanced signaling and altered food intake through both direct and indirect neural pathways.\u003c\/li\u003e\n\u003cli\u003eAdditionally, studies indicate Cagrilintide peptides may have effects on gastric emptying and glucose metabolism. Research suggests it may influence gastric emptying rate and possibly affect postprandial glucose excursions, potentially contributing to observed laboratory measurements.\u003c\/li\u003e\n\u003cli\u003eThe peptide's potentially long half-life, which may be achieved through specific molecular modifications, may allow for sustained receptor activation, possibly leading to more consistent effects compared to shorter-acting analogs.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Research Applications\" id=\"research-applications\"\u003eResearch Applications\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eThe following areas reflect commonly studied Cagrilintide peptide benefits within controlled research environments.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhysiological Processes: Research suggests it may influence physiological processes through possibly enhanced signaling and potentially altered intake.\u003c\/li\u003e\n\u003cli\u003eMetabolic Markers: Studies indicate it may influence laboratory markers and may offer potential for research in metabolic contexts.\u003c\/li\u003e\n\u003cli\u003eExtended Duration: The modified structure may provide a longer half-life compared to native amylin, potentially allowing for less frequent laboratory administration.\u003c\/li\u003e\n\u003cli\u003eGastric Function: Research suggests Cagrilintide peptides may influence physiological processes through possibly enhanced signaling and potentially altered intake.\u003c\/li\u003e\n\u003cli\u003eCombination Potential: Studies suggest there may be possible synergistic effects when examined with other metabolic agents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Observations in Studies\" id=\"observations-in-studies\"\u003eObservations in Studies\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eClinical research suggests Cagrilintide may be generally well-tolerated, with reported Cagrilintide side effects varying across study designs.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGastrointestinal observations during initial administration\u003c\/li\u003e\n\u003cli\u003eAdministration site reactions\u003c\/li\u003e\n\u003cli\u003eMild and transient nausea\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003eCagrilintide may represent an advancement in amylin analog research, with Cagrilintide peptides receiving increasing attention in the field of metabolic research. Its modified structure may provide enhanced pharmacokinetic properties while potentially maintaining the receptor activity of amylin. Current research suggests there may be promising applications in areas related to metabolism, with ongoing studies exploring additional research potential.\u003cbr\u003e \u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33894838\/\"\u003e\u003cu\u003eEnebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021 May 8;397(10286):1736-1748. doi: 10.1016\/S0140-6736(21)00845-X. Epub 2021 Apr 22. PMID: 33894838.\u003c\/u\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\"\u003e\u003cu\u003eLau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016\/S0140-6736(21)01751-7. Epub 2021 Nov 16. PMID: 34798060.\u003c\/u\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37364590\/\"\u003e\u003cu\u003eFrias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in metabolic studies: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016\/S0140-6736(23)01163-7. Epub 2023 Jun 23. PMID: 37364590.\u003c\/u\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0014299922006586\"\u003e\u003cu\u003eSimone A. Melander, Anna Katri, Morten A. Karsdal, Kim Henriksen, Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin, European Journal of Pharmacology, Volume 938, 2023, 175397, ISSN 0014-2999, https:\/\/doi.org\/10.1016\/j.ejphar.2022.175397.\u003c\/u\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.jmedchem.5b00726\"\u003e\u003cu\u003eLau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015 Sep;58(18):7370-7380. DOI: 10.1021\/acs.jmedchem.5b00726. PMID: 26308095.\u003c\/u\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--$!--\u003e\u003ctemplate data-dgst=\"BAILOUT_TO_CLIENT_SIDE_RENDERING\"\u003e\u003c\/template\u003e\n  \u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"\"\u003e\n  \u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n    \u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003e\n      Certificate of Analysis (COA)\n    \u003c\/h2\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"flex w-full flex-row flex-wrap gap-x-0 gap-y-4 md:gap-x-8\"\u003e\n  \n    \u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Cagrilintide-1.avif?v=1779876223\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Cagrilintide-1.avif?v=1779876223\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n\t\n\t\u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Cagrilintide-2.avif?v=1779876223\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Cagrilintide-2.avif?v=1779876223\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n  \u003c!--\/$--\u003e\u003cdiv data-scroll-name=\"Resource\" class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" id=\"resources\"\u003eResource\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-full\"\u003e\u003cdiv class=\"text-base text-[#4B5563]\"\u003e\u003cspan\u003eAll products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"10mg","offer_id":53240041996588,"sku":"PEP-VIL-CAG-10MG631936","price":65.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/cagrilintide-_1_-1740494943801.png?v=1779696836","url":"https:\/\/www.powerpieeptidesus.com\/products\/cagrilintide","provider":"Power Peptides","version":"1.0","type":"link"}